PortfoliosLab logoPortfoliosLab logo
CNCR vs. CEFS
Performance
Return for Risk
Dividends
Drawdowns
Volatility

Performance

CNCR vs. CEFS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Saba Closed-End Funds ETF (CEFS). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CNCR vs. CEFS - Yearly Performance Comparison


Returns By Period


CNCR

1D
0.00%
1M
0.00%
YTD
6M
1Y
3Y*
5Y*
10Y*

CEFS

1D
-0.62%
1M
-1.46%
YTD
0.51%
6M
4.83%
1Y
14.99%
3Y*
17.28%
5Y*
11.76%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


CNCR vs. CEFS - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is lower than CEFS's 3.80% expense ratio.


Return for Risk

CNCR vs. CEFS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CNCR

CEFS
CEFS Risk / Return Rank: 5959
Overall Rank
CEFS Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
CEFS Sortino Ratio Rank: 5757
Sortino Ratio Rank
CEFS Omega Ratio Rank: 6565
Omega Ratio Rank
CEFS Calmar Ratio Rank: 5151
Calmar Ratio Rank
CEFS Martin Ratio Rank: 6464
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. CEFS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Saba Closed-End Funds ETF (CEFS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

CNCR vs. CEFS - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


CNCRCEFSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.14

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.91

Sharpe Ratio (All Time)

Calculated using the full available price history

0.70

Dividends

CNCR vs. CEFS - Dividend Comparison

CNCR has not paid dividends to shareholders, while CEFS's dividend yield for the trailing twelve months is around 7.94%.


TTM202520242023202220212020201920182017
CNCR
Loncar Cancer Immunotherapy ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
CEFS
Saba Closed-End Funds ETF
7.94%7.84%8.79%9.20%11.32%10.73%8.61%8.10%10.43%5.02%

Drawdowns

CNCR vs. CEFS - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum CEFS drawdown of -38.99%. Use the drawdown chart below to compare losses from any high point for CNCR and CEFS.


Loading graphics...

Drawdown Indicators


CNCRCEFSDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-38.99%

+38.99%

Max Drawdown (1Y)

Largest decline over 1 year

-7.91%

Max Drawdown (5Y)

Largest decline over 5 years

-16.85%

Current Drawdown

Current decline from peak

0.00%

-2.94%

+2.94%

Average Drawdown

Average peak-to-trough decline

0.00%

-3.73%

+3.73%

Ulcer Index

Depth and duration of drawdowns from previous peaks

2.03%

Volatility

CNCR vs. CEFS - Volatility Comparison


Loading graphics...

Volatility by Period


CNCRCEFSDifference

Volatility (1M)

Calculated over the trailing 1-month period

4.96%

Volatility (6M)

Calculated over the trailing 6-month period

7.63%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

13.23%

-13.23%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

13.00%

-13.00%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

15.38%

-15.38%